BioCryst Pharmaceuticals, Inc. (BCRX)
NEUTRALFundamental
63
Precio
$9.83
Capitalización Bursátil
$2.43B
Parte 1 · Cuánto vale la empresa
Resumen
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$941M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-385M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$345M
Patrimonio Neto Total
$-119M
Pasivo Total
$633M
Ratio de Liquidez
2.32
Cobertura de Intereses
4.16
Deuda/EBITDA
1.20
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$26.93
Precio Actual
$9.83
Margen de Seguridad
+63.5%
Rango de Valor Justo
$20.10 - $33.76
Métodos de Estimación
Métricas de Valoración
Ratio P/E
7.86
ROE
-221.4%
Ratio P/B
-
P/FCF
6.73
Margen Bruto
97.8%
ROIC
-70.9%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-70.9%
WACC
9.0%
ROIC − WACC
-79.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (13)
- EPS shows upward trend
- Gross Margin 97.8%
- P/FCF 6.73
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Low reliance on intangibles
- DCF valuation (Undervalued)
- Revenue Growth 5Y 117.9%
- Analyst Consensus 88% Buy
- Piotroski F-Score 7/9
Fallido (8)
- Price CAGR 4.20%
- ROIC -70.9%
- Operating Margin -33.3%
- Return on Tangible Assets
- ROE -328.8%
- Earnings Surprise avg -35.2%
- Share Dilution 5.5%
- Net Margin Trend -40.9% vs -6.4%
No disponible (6)
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Charles K. Gayer | CEO, President & Director | 54 |
| Mr. Babar Ghias | CFO & Head of Corporate Development | 46 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 59 |
| Mr. John Ruesch | Chief Technical Operations Officer | - |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer | - |
| Nick Wilder | Manager of Investor Relations | - |
| Ms. Stephanie Angelini | Chief People Officer & Chief Communications Officer | - |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 70 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 72 |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer | - |
Riesgo de Auditoría
8
Riesgo del Consejo
3
Riesgo de Compensación
10
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for BCRX, sourced from Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. The transcript, which is available for review, details the company's financial performance and strategic outlook for the first quarter of 2026. Investors and analysts can access the full transcript to gain insights into the company's operational updates, pipeline progress, and future guidance. As this is an informational event, no immediate market reaction is implied without further specific financial data or forward-looking statements being disclosed within this summary.
via Markets Gazette